Treatment

Displaying 51 - 60 of 321

Trials demonstrate treatment for aggressive adenocarcinomas

Trials demonstrate treatment for aggressive adenocarcinomas
  Mutations in the KEAP1 gene could point the way to treating an aggressive form of lung cancer that is driven by “undruggable” mutations in the KRAS gene, according to a new study by MIT researchers. KEAP1 mutations occur alongside KRAS mutations in about 17% of lung adenocarcinoma cases.
3rd October 2017

HeartWare approved for destination therapy

HeartWare approved for destination therapy
  Medtronic plc has received FDA approval for its HeartWare HVAD System as a destination therapy for patients with advanced heart failure who are not candidates for heart transplants. The HVAD System, a left ventricular assist device or LVAD, helps the heart pump and increases the amount of blood that flows through the body.
2nd October 2017

HeartLight Excalibur Balloon receives CE Mark Approval

HeartLight Excalibur Balloon receives CE Mark Approval
CardioFocus has announced the European CE Mark approval of the HeartLight Excalibur Balloon, a next-generation technology designed for the treatment of atrial fibrillation (AF). The Excalibur Balloon leverages the proven universal balloon design of the company's FDA-approved HeartLight Endoscopic Ablation System and introduces an advanced feature set that optimises the speed and magnitude of target tissue contact during pulmonary vein isolation (PVI) procedures.
2nd October 2017


Nintendo Wii games to help Parkinson’s patients

Nintendo Wii games to help Parkinson’s patients
  A pair of Purdue University professors are using the popular Nintendo Wii gaming system to help people with Parkinson’s disease. Jessica Huber and Jeff Haddad from the College of Health and Human Sciences are studying how playing specially created games can improve a patient’s movement, speech and overall quality of life.
28th September 2017

Impella RP receives FDA PMA Approval

Impella RP receives FDA PMA Approval
Abiomed, Inc. has announced it has received U.S. Food and Drug Administration (FDA) pre-market approval (PMA) for the Impella RP heart pump. Culminating from five years of research, this approval follows the prior FDA Humanitarian Device Exemption (HDE) received in January 2015 and adds the Impella RP heart pump to Abiomed's platform of PMA approved devices.
26th September 2017

Regulator improves liver regeneration

Regulator improves liver regeneration
By performing large-scale proteomics analysis of liver proteins, ETH researchers have discovered a protein that is essential for liver regeneration. They have also figured out the mechanism of the protein’s function. The liver is a wonderful thing: it’s the only organ able to fully regenerate with no scar tissue formation, even after major injury. In the case of organ donation, it is therefore generally possible to remove part of the donor’s liver and implant it into another patient.
26th September 2017

CerebroFlo EVD Catheter receives FDA Clearance

CerebroFlo EVD Catheter receives FDA Clearance
Arkis BioSciences has obtained FDA clearance of its new external ventricular drainage catheter, CerebroFlo. According to Chad Seaver, CEO of Arkis BioSciences, the new catheter will be used for insertion into a ventricular cavity of the brain for external drainage of cerebrospinal fluid in patients with elevated intracranial pressure, intraventricular hemorrhage, or hydrocephalic shunt infections.
21st September 2017

Detachable coil system aids peripheral vasculature

Detachable coil system aids peripheral vasculature
At the ongoing Cardiovascular and Interventional Radiological Society of Europe (CIRSE) meeting in Copenhagen, Denmark, Medtronic has unveiled its new Concerto 3D Detachable Coil System. The device, which is now available to physicians in the U.S. and Europe, is intended to be used for embolisations in the peripheral arteries and veins. The device folds into a dense and knotty shape which helps to fill in an aneurysm, for example, similar to how neurovascular aneurysms are now commonly treated.
20th September 2017

Next-gen spinal cord stimulator receives FDA Approval

Next-gen spinal cord stimulator receives FDA Approval
Medtronic has announced FDA approval and U.S. launch of the Intellis platform for the management of certain types of chronic intractable pain. The Intellis platform was designed to overcome limitations with current spinal cord stimulation (SCS) systems, such as battery performance, and can power the EvolveSM workflow*, which standardises guidance and balances high-dose (HD) and low-dose (LD) therapy settings.
19th September 2017

Solution to bacterial antibiotic resistance may be found in plants

Solution to bacterial antibiotic resistance may be found in plants
Bacterial resistance to antibiotics is an ever-growing problem for healthcare, agriculture and hygiene, thanks to their indiscriminate and often excessive use. While natural, plant-derived antimicrobial small molecules may offer a potential solution, they often lack sufficient activity and selectivity to fulfil antibiotic requirements, and their conventional methods activation may not be compatible with biomedical applications.
12th September 2017


Treatment documents


Sign up to view our publications

Sign up

Sign up to view our downloads

Sign up

CES 2018
9th January 2018
United States of America Las Vegas, Nevada
Developing wearable products: technology and opportunities
17th January 2018
United Kingdom Cocoon Networks, London
Smart Mobility Executive Forum
12th February 2018
Germany Berlin
embedded world 2018
27th February 2018
Germany Nuremberg
Industry 4.0 Summit 2018
28th February 2018
United Kingdom Manchester